The launch highlights the growing maturity of India's nuclear medicine ecosystem.
A new study reveals that a copper-containing compound, Cu(ATSM), can repair vital waste-clearing pumps in the brain, significantly reducing toxic amyloid-beta proteins associated with Alzheimer's disease and improving long-term spatial memory in mouse models. This discovery offers a promising new therapeutic avenue for neurovascular dysfunction in Alzheimer's.
'They talked bad about our leaders. They said India was a dead economy. They were not sensitive to the Indian psyche.'
The Delhi Police registered 24 cases under the NDPS Act and arrested 23 persons during a week-long anti-drug campaign that combined enforcement with large-scale awareness drives.
A potential US-Iran peace deal, expected to be signed on June 19, is anticipated to ease geopolitical stress and benefit various sectors, particularly in India, with analysts suggesting investors await finer details before making significant moves.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Delhi Police arrested three men involved in an illegal network supplying banned pharmaceutical drugs across Delhi and the NCR. The accused, working as medical representatives, were caught with substantial quantities of psychotropic substances and controlled medicines.
Prime Minister Narendra Modi announced that the India-UK Comprehensive Economic and Trade Agreement (CETA) will come into effect on July 15, 2026, anticipating a significant boost to bilateral trade and investment.
A recently finalised peace deal between the US and Iran, set to be signed on June 19, is expected to significantly benefit India's economy by boosting exports to West Asia, stabilising the rupee, and easing inflationary pressures, according to exporters and experts.
Two former employees of a Delhi-based pharmaceutical firm have been booked for allegedly cheating, forging documents and impersonating to secure government tenders, including supplies to Army hospitals.
Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
An independent think tank on policing has called for a multi-agency investigation into the recent unearthing of a spurious Mounjaro (tirzepatide) injection manufacturing racket in Gurugram, offering free-of-cost forensic expertise.
Indian benchmark equity indices, Sensex and Nifty, saw gains in early trade, driven by strong performance in banking shares and positive sentiment from Asian markets, alongside optimism surrounding the ongoing US-China Summit.
Indian companies are increasingly opting for demergers, with 29 deals valued at over $40 billion in 2025 alone, marking a 10-year high, as promoters and boards recognise that markets favour focused businesses over complex conglomerates.
Nomura has increased its March 2027 target for the Nifty 50 to 25,900, driven by strong corporate earnings and attractive market valuations, even as risks from the West Asia conflict and high oil prices persist.
Over the past year, the sale of injectable GLP-1 agonists (used to treat type 2 diabetes and obesity) such as Mounjaro, Wegovy and Ozempic have surged a whopping 218 per cent.
American industry groups sought punitive tariffs on Indian goods at USTR hearings, while Indian officials defended the country's manufacturing growth as demand-led and WTO-compliant.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
India's pharmaceutical exports have shown robust growth, reaching over USD 28 billion, despite global economic challenges. The sector is projected to reach USD 130 billion by 2030.
'I own a few cars that I have had specified minutely to my taste, and it does feel nice to know that there are no other vehicles like them anywhere in the world.'
API Holdings, the parent company of online pharmacy PharmEasy, has significantly reduced its debt from 1,800 crore to 1,050 crore and refinanced it at lower interest rates under CEO Rahul Guha, shifting its focus from 'growth at any cost' to profitability and aiming for a debt-free balance sheet before a potential stock market listing.
Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.
India's exports recorded a 13.78 per cent increase to USD 43.56 billion in April, marking the highest monthly outbound shipments in over four years, primarily driven by petroleum products. However, the trade deficit widened to a three-month high of USD 28.38 billion due to a 10 per cent rise in imports.
Indian foreign direct investment (FDI) in the United States has reached approximately USD 16.4 billion, supporting around 70,800 jobs and contributing significantly to research and development, according to US Deputy Undersecretary Brandon Remington.
Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net profit falling 55 per cent to Rs 554.6 crore, missing consensus estimates. Despite strong growth in India and Africa, a significant decline in North American sales impacted overall performance, with the company now focusing on new product launches and regulatory filings to drive future gains.
The 100-day 'drug-free J-K campaign' has achieved significant success across the Union Territory, leading to numerous arrests, seizures of narcotics, and demolition of properties linked to drug peddlers.
Delhi Police have arrested four individuals involved in an interstate racket manufacturing and distributing counterfeit prescription drugs, uncovering an illegal processing unit in Delhi.
Authorities in Gurugram have uncovered a racket involved in the manufacturing and sale of fake Mounjaro (tirzepatide) injections, used for treating diabetes and obesity. Two people have been arrested, and a nationwide alert has been issued to trace counterfeit batches.
Indian stock markets saw a significant rebound, with the Sensex jumping nearly 790 points, primarily fuelled by strong buying interest in telecom, pharma, and private banking shares, despite a volatile trading session and a weakening rupee.
Indian benchmark equity indices, Sensex and Nifty, closed lower due to investor caution over rising bond yields, a weaker rupee, and fresh fuel price hikes, which have revived inflation concerns.
The Beijing summit may have reduced immediate diplomatic uncertainty, but it did not resolve the deeper structural contest between the United States and China. That contest appears likely to define the coming decade, notes Varun Arya.
Jammu and Kashmir Police chief Nalin Prabhat issued a stern warning to Pakistan-based gangster Shahzad Bhatti for 'pumping narcotics' into India, vowing to dismantle his network.
The Indian banking sector is projected to experience a steady 9-13 per cent industrial credit growth in the first half of 2026, driven by capital expenditure, infrastructure development, and sectoral demand recovery, according to a Ficci-IBA survey.
A new study suggests that newer oral weight loss drugs may do more than suppress appetite, potentially altering brain circuits that control motivation and reward, impacting how one experiences pleasure.
India's domestic pharmaceutical market recorded its highest value growth in five quarters during Q4 FY26, driven primarily by pricing and an early indication of volume recovery, with a significant structural shift towards chronic and sub-chronic therapies.
Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift towards newer, high-margin GLP-1 diabetes therapies. The company plans to expand its insulin presence across 80 markets, focusing on value maximisation and addressing the indispensable need for insulin, particularly for Type-1 and late-stage Type-2 diabetics.
India's foreign direct investment (FDI) inflows are projected to surpass $90 billion in 2025-26 (FY26), driven by robust policy reforms, free trade agreements, and strong economic growth, according to DPIIT Secretary Amardeep Singh Bhatia.
